Integrin alpha V beta 6 is a heterodimer of beta-6 associating with alpha-V. Integrin alpha-V beta-6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. Also, Integrin alpha-V beta-6 acts as a receptor for coxsackievirus A9 and coxsackievirus B1 as well as herpes simplex virus-1/HHV-1. Furthermore, it binds the TGF-beta latency‑associated peptide (LAP) and activates TGF-beta 1 or TGF-beta 3 from large latent complexes. This activation requires interaction with LTBP-1 and fibronectin, and is enhanced by PAR-1.
Integrin alpha V beta 6 Product List
No Data
You Have Viewed 0 Of 0 Results
1
No Data
No Data
Can’t find what you need?
Submit your requirements and our technical team will help.
When should I choose Avitag™-based or primary-amine biotinylated TfR1?
Avitag™ provides site-specific biotinylation and more controlled orientation for quantitative SPR, BLI, or ELISA. Primary-amine labeling can increase signal through multiple biotins but is more heterogeneous, so epitope accessibility should be verified.
Q
How can recombinant TfR1 and a TfR1 stable cell line be combined during shuttle or antibody screening?
Recombinant TfR1 supports controlled affinity and cross-species comparisons. A TfR1 stable cell line then tests cell-surface recognition and target engagement before transcytosis-specific models are introduced.
Q
Why can the highest-affinity TfR1 binder be a poor blood–brain barrier shuttle candidate?
TfR1-mediated transport depends on affinity, valency, and intracellular trafficking. Very tight or bivalent binding can favor receptor retention, so protein-based affinity ranking should be followed by cell transcytosis and in vivo studies.
Q
What do SEC-MALS and SPR answer separately when qualifying a DLL3 reagent?
SEC-MALS assesses molecular weight and homogeneity in solution, whereas SPR confirms binding kinetics with a relevant antibody or ligand. Together they help separate aggregation-related signal from functional target recognition.
Q
How should a DLL3 cross-reactivity panel be designed for preclinical development?
Compare human DLL3 with the homolog from the intended animal model, such as cynomolgus, rhesus, mouse, or rat. Use matched construct boundaries and assay formats so affinity differences reflect species rather than reagent design.
Great communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!